XCUR Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.490

Open

2.345

VWAP

2.30

Vol

53.02K

Mkt Cap

14.72M

Low

2.100

Amount

121.95K

EV/EBITDA(TTM)

--

Total Shares

6.37M

EV

12.12M

EV/OCF(TTM)

--

P/S(TTM)

--

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Show More

Events Timeline

(ET)

2026-06-01

16:10:00

Exicure Receives Compliance Notice from Nasdaq

2026-02-05 (ET)

2026-02-05

07:10:00

Exicure Publishes Phase 2 Study Results for Burixafor

2025-12-08 (ET)

2025-12-08

16:40:00

Exicure Announces Phase 2 Trial Results for Multiple Myeloma Treatment

2025-12-05 (ET)

2025-12-05

11:10:00

Exicure Inc Trading Resumes

2025-12-05

11:00:00

Exicure Inc Trading Halted Due to Volatility

2025-08-01 (ET)

2025-08-01

16:03:44

Exicure completes last patient in Phase 2 GPC-100 combo trial

2025-07-14 (ET)

2025-07-14

11:46:17

Exicure files to sell 5.16M shares of common stock for holders

2025-05-28 (ET)

2025-05-28

16:59:56

Exicure receives Nasdaq delinquency notice on late Form 10-Q filing

2025-05-05 (ET)

2025-05-05

09:22:52

Exicure completes patient enrollment in GPC-100 trial

News

NASDAQ.COM

06-11NASDAQ.COM

Exicure Faces Nasdaq Delisting Risk Due to Equity Shortfall

NASDAQ.COM

06-02NASDAQ.COM

Exicure Receives Nasdaq Compliance Notification Due to Delayed 10-Q Filing

seekingalpha

06-01seekingalpha

Exicure Receives Nasdaq Non-Compliance Notice

NASDAQ.COM

04-23NASDAQ.COM

Exicure Partners with Adbiotech for Burixafor Development

Newsfilter

04-23Newsfilter

Exicure Partners with Adbiotech for Burixafor Development

Yahoo Finance

04-23Yahoo Finance

Exicure Partners with Adbiotech for Combination Therapy Development

Valuation Metrics

The current forward P/E ratio for Exicure Inc (XCUR.O) is 0.00, compared to its 5-year average forward P/E of -0.52. For a more detailed relative valuation and DCF analysis to assess Exicure Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.52

Current PE

0.00

Overvalued PE

0.35

Undervalued PE

-1.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

1.21

Current PS

0.00

Overvalued PS

3.06

Undervalued PS

-0.64

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

ué penny stocks tienen volumen inusual hoy

Intellectia · 3 candidates

Price: <= $5.00Relative Vol: >= 3List Exchange: XNYS, XNAS, XASEMin5 Price Change Pct: >= $5.00

Ticker

Name

Market Cap$

Pop Culture Group Co Ltd

29.50M

Exicure Inc

18.17M

SU Group Holdings Ltd

4.46M

Whales Holding XCUR

Trading Trends

People Also Watch

Frequently Asked Questions

What is Exicure Inc (XCUR) stock price today?

The current price of XCUR is 2.31 USD — it has increased 7.44

What is Exicure Inc (XCUR)'s business?

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

What is the price predicton of XCUR Stock?

Wall Street analysts forecast XCUR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XCUR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Exicure Inc (XCUR)'s revenue for the last quarter?

Exicure Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Exicure Inc (XCUR)'s earnings per share (EPS) for the last quarter?

Exicure Inc. EPS for the last quarter amounts to -0.29 USD, decreased -159.18

How many employees does Exicure Inc (XCUR). have?

Exicure Inc (XCUR) has 8 emplpoyees as of June 20 2026.

What is Exicure Inc (XCUR) market cap?

Today XCUR has the market capitalization of 14.72M USD.